Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Loukia Apostolakopoulou has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Burcu Polat

    School of Medicine, Department of Neurology, Istanbul Medipol University, Istanbul, Turkey

    2 shared publications
  • Paolo Martelletti

    Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy

    2 shared publications
  • Adina Maria Roceanu

    Neurology Department, University Emergency Hospital Bucharest, 020021 Bucharest, Romania

    1 shared publication
  • Alberto Raggi

    Neurology, Public Health and Disability Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

    1 shared publication
  • Alfons Macaya

    Pediatric Neurology Research Group Vall d'Hebron Research, Institute Autonomous University of Barcelona Barcelona, Spain

    1 shared publication
  • Alo-Rainer Leheste

    Neurology Clinic, Department of Neurology, Tartu University Hospital, Tartu, Estonia

    1 shared publication

Latest Publications

  • Open Access

    Resting EEG partial coherence demonstrates increased γ range central functional connectivity in amnestic mild cognitive impairment

    by Ioannis Vlachos, Christos Moschovos, Loukia Apostolakopoulou, Kyriaki Karasavvidou, Eva Ntanasi, Eirini Mamalaki, Dimitris Kugiumtzis, Vasilios K. Kimiskidis, Nikolaos Scarmeas, Andreas Kyrozis

  • Open Access

    COVID-19 vaccination-related headache showed two different clusters in the long-term course: a prospective multicenter follow-up study (COVA-Head Study)

    by Arife Çimen Atalar, Ayşe Nur Özdağ Acarlı, Betül Baykan, Paolo Martelletti, Hayrunnisa Bolay, Mustafa Ertaş, Esme Ekizoğlu, Ömer Karadaş, Burcu Polat, Işıl Yazıcı Gençdal, et al.

    Background: Although acute headache following COVID-19 vaccination is widely acknowledged, the long-term progression of these headaches remains poorly understood. Our objective was to identify various phenotypes of prolonged or worsened headaches associated with COVID-19 vaccination and document any changes in these phenotypes over an extended period. Additionally, we aimed to document the diverse headache presentations among patients with pre-existing primary headaches. Methods: A multinational, prospective observational study was conducted to investigate prolonged or worsened headaches associated with COVID-19 vaccination. Questionnaires assessing COVID-19 vaccination-related headaches at three time points (initial visit, 3rd month follow-up, and 6th month follow-up) were developed for the study. Headache specialists/clinicians evaluated patients using these questionnaires in a prospective manner. Repeated K-means cluster analysis was performed to identify patient profiles with prolonged or worsened headaches related to COVID-19 vaccination. Results: Among the 174 patients included in the study, there was a female-to-male ratio of 128 (73.6%) to 46 (26.4%). The mean age of the patient group was 45.2 ± 13.3 years, and 107 patients (61.5%) had a pre-existing history of primary headaches. Through the analysis, two major clusters were identified based on headache characteristics at each visit. During the first visit (n = 174), Cluster 1 primarily comprised patients with a history of primary headaches, frontal localization of pain, throbbing pain type, more severe headaches accompanied by symptoms such as nausea, phonophobia, photophobia, and osmophobia, and worsened by physical activity. In contrast, Cluster 2 consisted of patients with longer headache durations (over one month) and a stabbing/pressing quality of pain. Patients in Cluster 1 had a higher prevalence of migraine as the pre-existing primary headache disorder compared to Cluster 2 (90.48% vs. 68.18%, respectively; p = 0.005). Conclusion: The identification of two distinct phenotypes of prolonged or worsened headaches related to COVID-19 vaccination can provide valuable clinical insights. Having an awareness of the potential worsening of headaches following COVID-19 vaccination, particularly in patients with a primary headache disorder such as migraine, can help clinicians and headache experts anticipate and adjust their treatment strategies accordingly. This knowledge can aid in preplanning treatment modifications and optimize patient care.


  • Open Access

    Intravenous topiramate for seizure emergencies – First in human case report

    by Loukia Apostolakopoulou, Pilar Bosque Varela, Fabio Rossini, Ciara O'SUllivan, Wolfgang Löscher, Giorgi Kuchukhidze, Eugen Trinka


  • Bilateral wallerian degeneration of middle cerebellar peduncles following unilateral pontine infarction

    by Loukia Apostolakopoulou, Argyro Tountopoulou, Eirini Pantou

    Bilateral lesions of medial cerebellar peduncles are rare and are most frequently observed in acute cerebral infarction due to large-artery atherosclerosis, wallerian degeneration, neurodegenerative diseases (i.e. multiple system atrophy), inflammatory diseases (i.e. neuromyelitis optica, acute demyelinating encephalomyelitis), toxic encephalopathies (i.e. heroin abuse) and primary central nervous system lymphomas [3]. Wallerian degeneration regards progressive anterograde demyelination of the distal axons following injury to the proximal axon. As a result, fibrosis and atrophy of the affected fiber tracts occurs [2]. We present a case report of a patient with the rare finding of bilateral middle cerebral peduncle lesions, due to wallerian degeneration following pontine infarction. We further discuss differential diagnosis upon imaging findings and their clinical utility.

  • Open Access

    Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis

    by Matteo Castaldo, Marta Waliszewska-Prosół, Maria Koutsokera, Micaela Robotti, Marcin Straburzyński, Loukia Apostolakopoulou, Mariarita Capizzi, Oneda Çibuku, Fidel Dominique Festin Ambat, Ilaria Frattale, et al.

    Background: Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are used to reduce the risk of developing Coronavirus Disease 2019 (COVID-19). Despite the significant benefits in terms of reduced risk of hospitalization and death, different adverse events may present after vaccination: among them, headache is one of the most common, but nowadays there is no summary presentation of its incidence and no description of its main features. Methods: We searched PubMed and EMBASE covering the period between January 1st 2020 and August 6th, 2021, looking for record in English and with an abstract and using three main search terms (with specific variations): COVID-19/SARS-CoV-2; Vaccination; headache/adverse events. We selected manuscript including information on subjects developing headache after injection, and such information had to be derived from a structured form (i.e. no free reporting). Pooled estimates and 95% confidence intervals were calculated. Analyses were carried out by vaccine vs. placebo, by first vs. second dose, and by mRNA-based vs. “traditional” vaccines; finally, we addressed the impact of age and gender on post-vaccine headache onset. Results: Out of 9338 records, 84 papers were included in the review, accounting for 1.57 million participants, 94% of whom received BNT162b2 or ChAdOx1. Headache was generally the third most common AE: it was detected in 22% (95% CI 18–27%) of subjects after the first dose of vaccine and in 29% (95% CI 23–35%) after the second, with an extreme heterogeneity. Those receiving placebo reported headache in 10–12% of cases. No differences were detected across different vaccines or by mRNA-based vs. “traditional” ones. None of the studies reported information on headache features. A lower prevalence of headache after the first injection of BNT162b2 among older participants was shown. Conclusions: Our results show that vaccines are associated to a two-fold risk of developing headache within 7 days from injection, and the lack of difference between vaccine types enable to hypothesize that headache is secondary to systemic immunological reaction than to a vaccine-type specific reaction. Some descriptions report onset within the first 24 h and that in around one-third of the cases, headache has migraine-like features with pulsating quality, phono and photophobia; in 40–60% of the cases aggravation with activity is observed. The majority of patients used some medication to treat headache, the one perceived as the most effective being acetylsalicylic acid.


  • The genetic etiology in cerebral palsy mimics: The results from a Greek tertiary care center

    by Vasiliki Zouvelou, Delia Yubero, Loukia Apostolakopoulou, Eleftheria Kokkinou, Manolis Bilanakis, Zoi Dalivigka, Ioannis Nikas, Elissavet Kollia, Belen Perez-Dueñas, Alfons Macaya, et al.